(Q32076730)

6 July 2017

0 references

Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention (English)

1 reference

6 July 2017

1 reference

D L Brown

1 reference

6 July 2017

C S Fann

series ordinal

1 reference

6 July 2017

C J Chang

series ordinal

1 reference

6 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

American Journal of Cardiology

6 July 2017

published in

1 reference

6 July 2017

1 reference

6 July 2017

1 reference

6 July 2017

page(s)

537-541

1 reference

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

6 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901427-2

Glycoprotein IIb/IIIa integrin blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901427-2

Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901427-2

GPIIb-IIIa: the responsive integrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901427-2

Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901427-2

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901427-2

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901427-2

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901427-2

Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901427-2

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901427-2

Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901427-2

10.1016/S0002-9149(00)01427-2

7 January 2021

Identifiers

DOI

1 reference

6 July 2017

1 reference